Andrew McKee shares an article on the latest developments in Ulcerative Colitis.
Many of our clients are pursuing groundbreaking therapies in disease areas with high unmet medical needs, giving our firm the chance to become intimately familiar with some of the most exciting areas in drug development. One disease area that is receiving a lot of attention is Inflammatory Bowel Disease (IBD), where the disease burden and the need for novel, efficacious therapeutics remain high. Below, we’ll share our thoughts on the current landscape in Ulcerative Colitis (UC), one of the main diseases associated with IBD, and what we’re looking forward to.
Ulcerative Colitis is characterized by recurring episodes of inflammation limited to the mucosal layer of the colon. It commonly involves the rectum and may extend to involve other parts of the colon. The onset of symptoms is usually gradual, with symptoms progressing over several weeks, and can range from mild disease (<4 stools per day) to severe disease (>10 stools per day with severe cramps and continuous bleeding).
Most patients with UC are treated with pharmacological therapy, with the goals of inducing and maintaining endoscopic and clinical remission. The cornerstone treatment for severe UC is anti-tumor necrosis factor (TNF) therapy, including infliximab (Remicade), adalimumab (Humira), and golimumab (Simponi). Unfortunately, these therapies leave much to be desired, with ~10-30% of patients not responding to initial treatment, and ~23-46% of treated patients losing response over time.
Key points include:
- The treatment landscape
- The FDA response
- Results from clinical trials
Read the full article, Developments in Ulcerative Colitis, on HeadlandStrategy.com.
Umbrex is pleased to welcome David Madukauwa-David. David, previously a generalist at BCG, recently kicked off his own consulting firm focused on corporate strategy/M&A in healthcare. Prior to BCG, he was an engineer and researcher, working at Georgia Tech, IFSTTAR, CEA, and Airbus among others. David has deep expertise in new product development within medical devices/medtech but has led cross-functional engagements across a wide range of industries.
He lives in Atlanta, GA with his wife and their two furry kids. David is open to collaborating on corporate strategy projects in healthcare/life sciences on mainland US.
Umbrex is pleased to welcome Ashish Vatsal with Vatsal Consulting Group. Ashish is an independent consultant interested in combining strategy, implementation, and data for values-driven organizations that recognize financial return is just one dimension of success. He most recently spent eight years as a Managing Consulting, Owner, and Account Leader at Point B and started his own consulting firm earlier this year.
Prior to Point B, he was consultant with BCG Chicago. Prior to that, Ashish was an investment analyst at an event-driven hedge fund from 2005-2009 (yikes!). He has worked across a variety of industries, including healthcare, retail, and media. Ashish received his MBA from the University of Michigan, and his BS in Computer Science from Yale University.
He lives in Portland, OR with his wife, toddler, and rescue dog. In his spare time he likes to imagine what it was like to have spare time
Umbrex is pleased to welcome Sven Sauer with SVEN SAUER HEALTHCARE CONSULTING. Sven has over 25 years of experience in pharma and healthcare with deep knowledge and understanding of the German and various other European healthcare systems. In 2011, he founded SVEN SAUER HEALTHCARE CONSULTING, which successfully provides services to the pharmaceutical and medical devices industry in Germany and Europe.
Prior to that he held several senior executive roles with Eli Lilly in Germany, the US and across Europe; and he worked for McKinsey, consulting payers and pharma companies nationally and internationally. He started his medical career in neurology/neuroradiology, and gained legal experience in malpractice/physicians’ law.
Sven holds degrees in law from Mainz university, and medicine from Frankfurt university, and is fully licensed in both professions.
Sven is happy to work on pricing, reimbursement and market access projects as well as business development topics for pharmaceutical and medical devices companies in Germany and Europe
In this post from his popular Boundless newsletter, Paul Millerd asks, “Do we design life around learning? Or do we hardly fit it in? Do we really need to learn that much to live a decent life?” He shares thoughts and experiences on learning Chinese, and the U.S. Healthcare crisis.
#1 On Learning Chinese
I’ve been busy the past two weeks going to Chinese class for three hours and then studying another two or three hours every day at home. I was a bit stressed before the class started but have been surprised at how much I’ve enjoyed the classes.
This shouldn’t be a surprise. I’ve been transported back to campus and now remember how much I loved being in school. I still claim to love learning but if I am honest I don’t do much of it. I imagine I’m like most people. I learn a lot of new things by solving problems. This is one reason I like self-employment. It forces you to learn many different things. But these are all small things. Like learning SEO. Or learning basic CSS and HTML. You can get to a good understanding of those topics in less than a week.
I haven’t spent much time in the deep, focused state that brings me back to studying engineering in school. The state in which you are slightly beyond your current capabilities and that if you trust the system you will eventually arrive at the answer. I loved that.
I’ve gotten better at writing but I also have a suspicion that I might have improved faster if I gave it more focused attention. The kind of environments that can enable deep learning are magical and we probably don’t give them enough credit in the non-stop criticism of higher education. Higher education has lots of problems but in most schools there are those magical programs and professors that can help enable this kind of learning.
Key points include:
- The learning design
- The healthcare system
Read the full post, Lessons from Learning Chinese, on boundless.com.
Umbrex is pleased to welcome Francesca Muller with Francesca Muller Ltd. Francesca started her career as a senior associate at McKinsey, where she worked in the media practice in New York and then London. She has been working as an independent consultant since 2004, leading growth strategy and transformation projects across a range of sectors including healthcare, financial services, environmental, B2B and industrial services.
She has a BA and JD from Harvard University and currently lives in London with her husband and two children.
Umbrex is pleased to welcome Nilesh Rajadhyax with Vyom Health. Nilesh is a seasoned executive with 15+ years of experience in the Healthcare sector primary serving payers and providers. He was an Associate Partner at McKinsey and Company and advised clients on strategy, technology and acquisitions in healthcare. He served some large Health systems, a large national payer, a large healthcare technology company and many middle market private equity funds.
He then joined TransUnion’s Healthcare division and successfully, built a data business line from scratch. While at TransUnion he served as the GM for couple product lines, led the billing and sales operations functions and also led the merger and acquisitions team for the Healthcare division. He was part of TransUnion’s journey to IPO from a private equity ownership and understands the aspects of leading and operating under both ownership structures.
He most recently was with Heartland Dental, a large roll-up of ~1000 dental offices and was the Service line GM for Invisalign and Endodontics (root canals) across the organization. He led the marketing, training, payer management, financing and vendor management functions to grow the service lines and understands the mechanics of a multi-site provider network.
Nilesh would like to collaborate on projects of growth, process improvements, corporate development and strategy in the area of Healthcare providers, payers and Healthcare technology and services.
Umbrex is pleased to welcome Willem Koelewijn. Willem is an independent healthcare services entrepreneur. After several years in management consulting (McKinsey) and telecoms, marketing 3G equipment to operators in Europe, Willem set a several Ambulatory Surgery Centres in the Netherland under the Alant Medical brand name. These clinics were merged with Bergman Clinics to become the largest chain of private clinics in the Netherlands. He served on the board as COO. He subsequently became an independent healthcare entrepreneur working in various parts of the Dutch healthcare system: from pain clinics, to midwife led maternity care to developing assisted living facilities for seniors.
Umbrex is pleased to welcome Alex Jacobs-Hajian. Alex is a C-Level Strategy and Operations Management Consultant focused on Mergers and Acquisitions, Deep Technical Know-How, and Business & Legal Acumen
• Program and Project Management
• Client Relationship Management and Value Realization
• Digital and Technology Strategy
• Lean Six Sigma Certified
• Resources and Utilities
• Communications, Media, and Technology
• Healthcare and Life Sciences
• Government and Public Service
Umbrex is pleased to welcome David Edelman. After 30 years as a Chief Marketing Officer (at Aetna/CVS) and building consultancy businesses in Digital and Marketing Transformation (with McKinsey, Digitas, and the Boston Consulting Group), I would love to work with others on helping companies in healthcare, fin services, consumer services, and marketing tech/svcs shape their strategic direction, build their teams’ capabilities, and become more digitally agile. I know what it takes from the top strategic level down to the nitty gritty of tech, ops, and creative to get great marketing done.
I am also open to appropriate opportunities on boards, and am currently on two non-profit boards — The Walnut Hill School for the Arts, and the Boston Ad Club — where I serve on the strategy committees, building a future direction for both institutions to expand their impact.
I’ve published in HBR, speak frequently at industry conferences and events, and blog on topics ranging from digital marketing to the Customer Decision Journey. But most importantly, I am also a music fanatic and play saxophone.
Umbrex is pleased to welcome Seth Townsend with Tonisgah Group. Seth spent 5 years at McKinsey as part of the Healthcare practice, leading efforts across sales growth, pricing, operations, due diligence, M&A, and corporate strategy for companies in the pharmaceuticals, medical devices, and healthcare industry. Following his time at McKinsey, Seth worked at Novartis where he held roles in Commercial, Shared Services, Finance, and Operations in both the US and Switzerland. He was most recently Head of Commercial Support Operations in the Sandoz Division, a global leader in generics and biosimilars where he led a team of over 30 people across insights & analytics, salesforce effectiveness, sales training, and data services. Seth was the SVP Transformation for Beacon Health Options, the largest private behavioral health company with sales of over $2B (now a part of Anthem). There, he led initiatives across transaction management, margin improvement / value creation, and organizational restructuring.
Seth holds a Global Executive MBA with distinction from INSEAD, a PhD in Biological Engineering from MIT, and a BS in Biomedical Engineering from Johns Hopkins University. Seth lives with his wife and two daughters in New York. He would be happy to collaborate on projects in the pharmaceutical, healthcare, and private equity industries.
Umbrex is pleased to welcome Przemek Czerklewicz. Przemek worked as a specialist consultant focused on end-to-end support for M&As in the strategy practice at McKinsey. In 2017 he started his independent consultancy, advising on transactions, technology strategy and innovation.
Przemek has been responsible for over 30 due diligence and acquisition screening studies, both for financial and industrial buyers. Most of his Clients are healthcare institutions, pharmaceuticals, medical devices, as well as high tech and social sector organizations. He has also managed pro bono projects in Eastern Europe and the Middle East, helping rising startups, local producers and farmers.
Umbrex is pleased to welcome Sean Folan. Sean is a versatile brand growth strategist with deep expertise leveraging insights and analytics to build and activate brand strategies and growth plans for clients in healthcare, consumer products, hospitality, aviation, telecom and financial services. His work has ranged from category and brand creation to product/service innovation, launch planning and campaign development/execution.
Sean and his family live in Connecticut where they enjoy hiking, biking and spending time with friends. He is looking to collaborate on projects involving brand growth strategy development and execution in the US, regionally, or globally.
Umbrex is pleased to welcome Kordt Griepenkerl with Med-Beratung. Kordt spent five years in the McKinsey healthcare practice in Germany and then worked in leadership positions for the medtech firms Biotronik and Trumpf Medical (now part of Hill-Rom). He covers a wide range of fields from operations to sales and marketing and extensive international experience. He and has been running his own consulting firm Med-Beratung UG since 2012.
Prior to McKinsey, Kordt obtained this PdD in theoretical physics. He lives in Reutlingen, South of Stuttgart, Germany.
In his spare time, he tries to improve this skill on his trombone and baritone horn as well as getting up to speed, running in the hills behind his house.
Kordt is happy to collaborate on projects in the healthcare industry.
Umbrex is pleased to welcome Ryan Wilber. Ryan has spent the past 10 years working with healthcare providers to design and implement innovative solutions to pressing care delivery challenges. His experience spans working with small community hospitals, large academic research centers, and integrated multi-hospital systems in the US and internationally to assess and implement new processes and technologies.
While his clients have been varied, his work has had in common a focus on addressing the core provider challenges around access, cost of care, patient experience, and quality. Increasingly, this work has centered on digital and virtual solutions. He believes the most effective solutions to healthcare challenges combine process and culture change with innovation and technology. To that end, he also works with a Bay Area venture fund to assess emerging healthcare technologies and advises their healthcare-focused portfolio companies on how to meet the needs of healthcare providers.
Umbrex is pleased to welcome Christian Frank with Redwood Wellness Partners. Christian Frank spent 8 years at McKinsey in Germany (Automotive, Operations, Sales and Marketing) and the US (HighTech, Healthcare, IT). After working at IBM in corporate strategy, SMB strategy and Healthcare Business Process Outsourcing he joined ADP as head of corporate strategy and employer services marketing. Following ADP he founded an employee wellness screening company and has been working as an independent consultant for the past 8 years.
Umbrex is pleased to welcome Jeff Boschwitz with JSB Consulting. Dr. Jeff Boschwitz has spent the last four years as an independent consultant focused on growth/new product and operations strategy for healthcare companies. Prior to that Jeff was COO of Personal Genome Diagnostics, EVP of Operations and Corporate Development at PLUS Diagnostics, VP Sales and Marketing for Orchid Cellmark and Director of Marketing Strategy and Analysis for Quest Diagnostics. Prior to going to industry, Jeff spent 10 years in consulting, the last five at Booz Allen Hamilton where he was a Principal in the healthcare practice.
Jeff received his PhD in Microbiology and Immunology from Cornell University and completed his Post-Doctoral work at Stanford University. He lives near Princeton NJ with his wife and spends his spare time with his racehorses. Jeff specializes in business unit, asset monetization, and cost reduction strategies and is happy to collaborate with anyone pursuing projects of this type for healthcare clients.
Umbrex is pleased to welcome Marla Malluk Gozman. Marla Malluk Gozman spent nearly ten years at Bain & Company in their Boston, London, and New York City offices. Since then, she has been an independent strategy consultant and also spent three years as Sales Strategy Director with Zearn, a nonprofit education technology organization. Marla has expertise in growth strategy and strategic planning, market and competitive analysis, and pricing, as well as advising start-up and nonprofit organizations. She has experience in many sectors, including health care, education, consumer finance, retail, hospitality, and telecommunications. Marla lives in northern New Jersey with her husband and son. She is happy to collaborate on growth strategy and market/competitive analysis projects in the greater New York City area.
Joyjit Saha Choudhury takes a look ahead to determine the effect of COVID-19 on health plans.
COVID-19 has upended our society, economy and the healthcare ecosystem in particular, and tremendous efforts are underway to try and manage the epidemic. In this difficult and unsettling time, I wanted to help think ahead to actions US-based payors and providers should take for a post-COVID-19 world.
This piece is structured in three parts – part 1 outlines likely strategic changes to the payor-provider landscape in the near- to medium-term; part 2 serves to remind the industry about what will likely NOT change in the long-term; finally, in light of parts 1 and 2, part 3 lays out six major actions payors and providers should take for a post-COVID-19 world.
Areas covered in this article include:
- Changes in the payor-provider landscape in the near- to medium-term
- What will not change in the payor-provider landscape in the long-term
- Actions payors and providers should take for success in a post-COVID-19 world
Read the full article, Six Actions U.S. Payors Providers Should Take for a Post COVID-19 World, on LinkedIn.
Umbrex is pleased to welcome Tushar Srivastava. Tushar is an independent strategy consultant who started his consulting career at McKinsey where he spent more than 3.5 years working as a generalist, eventually developing a spike in healthcare and life sciences. He has spent more than 3 years working as an Independent with multiple projects in pharma, life sciences, medical technology and healthcare.
Functionally, he is comfortable working on strategy initiatives across R&D, marketing, operations, technology, and pre-sales. He is open to collaborating on projects and supporting (research/analytics) clients without a restriction on geography, he has worked on projects in North America, Europe and APAC.
Posted on Jim Price’s company blog is a downloadable white-paper that explores the role of automation in healthcare.
As discussed in Issue One, the future of medicine will be fundamentally reshaped by a fusion of three forces: Genetics, Artificial Intelligence (AI) and automation. The future of interventional and surgical capabilities has not been widely discussed. Demand for these services has risen dramatically in recent years and is forecast to increase significantly in the coming decades. As a result, demand is quickly overtaking supply in surgical and procedural services; however, current payment systems cannot support the labor intensive model. AI, advanced robotics, 5G Internet, 3D printing, miniaturization, and nano technology will eventually fuse together to dramatically automate surgical and procedural services, alleviating the manpower shortage.
Included in this paper are:
- FDA approved AI applications
- Reimagining the future of surgery
- The performance of a pre-op robot
Download the full paper, Automated Medicine: The Future of Healthcare?, on the Progressive Healthcare Inc. website.
Umbrex is pleased to welcome Brett Pentz. Brett has 12+ years of management consulting and client services experience, delivering a range of strategy engagements for corporate, private equity, and public sector clients across industry, mostly focused in Healthcare and Technology. Brett’s management consulting work spans formative skills and credentials developed at Bain & Company, followed by contributions to position Teneo’s management consulting capabilities to reflect its brand as the global CEO advisory firm. Brett also possesses strong implementation and value delivery credentials from his years as a healthcare software implementation specialist for leading electronic medical record vendor Epic.
Brett primarily focuses on roles and projects where his experience and educational background can add the most value, often serving health and wellness-focused services and technology platform-focused companies, but he has demonstrated successful outcomes as a generalist at Bain and Teneo across a range of industries and project types. Specialties include corporate/BU strategy and planning, sales and marketing effectiveness, commercial due diligence and post-acquisition value creation, and target operating model and organizational design.
Brett lives in Montreal, Canada with his wife, after moving there two years ago from London, England – all part of his American expat adventures. He is happy to collaborate on any projects, particularly in the northeast (of the US and Canada).
Umbrex is pleased to welcome Justin Lechner with Bonsai Growth. Justin Lechner is an ex-Bain consultant based in Brooklyn, NY. After leaving Bain, Justin has split his time between ventures in the enterprise AI space and independent consulting work (innovation and technology projects).
Justin’s particularly passionate about applications of data science within the Consumer, Healthcare, and PE spaces. Justin is excited to collaborate on projects with a data focus